CN109929036A - A kind of antibody screening method that epitope is special and the antibody screened - Google Patents
A kind of antibody screening method that epitope is special and the antibody screened Download PDFInfo
- Publication number
- CN109929036A CN109929036A CN201711375292.7A CN201711375292A CN109929036A CN 109929036 A CN109929036 A CN 109929036A CN 201711375292 A CN201711375292 A CN 201711375292A CN 109929036 A CN109929036 A CN 109929036A
- Authority
- CN
- China
- Prior art keywords
- seq
- antibody
- ser
- epitope
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000012216 screening Methods 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 title claims abstract description 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 14
- 201000011510 cancer Diseases 0.000 claims abstract description 9
- 208000026278 immune system disease Diseases 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 58
- 150000001413 amino acids Chemical class 0.000 claims description 42
- 235000001014 amino acid Nutrition 0.000 claims description 22
- 230000014509 gene expression Effects 0.000 claims description 18
- 102000001189 Cyclic Peptides Human genes 0.000 claims description 15
- 108010069514 Cyclic Peptides Proteins 0.000 claims description 15
- 241001515965 unidentified phage Species 0.000 claims description 15
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- 235000018417 cysteine Nutrition 0.000 claims description 9
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- 230000008878 coupling Effects 0.000 claims description 4
- 238000010168 coupling process Methods 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000007790 solid phase Substances 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- 101710160107 Outer membrane protein A Proteins 0.000 claims description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 claims description 2
- 230000003321 amplification Effects 0.000 claims description 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 2
- 230000009870 specific binding Effects 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003446 ligand Substances 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 238000010171 animal model Methods 0.000 abstract description 4
- 238000012917 library technology Methods 0.000 abstract description 3
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 68
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 68
- 229960002621 pembrolizumab Drugs 0.000 description 27
- 229960003301 nivolumab Drugs 0.000 description 19
- 239000011324 bead Substances 0.000 description 17
- 241000282414 Homo sapiens Species 0.000 description 16
- 238000012360 testing method Methods 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 108010074708 B7-H1 Antigen Proteins 0.000 description 11
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 230000035772 mutation Effects 0.000 description 8
- 102220330185 rs1364834319 Human genes 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- RXUOAOOZIWABBW-XGEHTFHBSA-N Ser-Thr-Arg Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RXUOAOOZIWABBW-XGEHTFHBSA-N 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 238000009739 binding Methods 0.000 description 5
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
- 108010037850 glycylvaline Proteins 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- PVMPDMIKUVNOBD-CIUDSAMLSA-N Leu-Asp-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O PVMPDMIKUVNOBD-CIUDSAMLSA-N 0.000 description 4
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 4
- 230000008827 biological function Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000012875 competitive assay Methods 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 108010017391 lysylvaline Proteins 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 3
- ARHJJAAWNWOACN-FXQIFTODSA-N Ala-Ser-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O ARHJJAAWNWOACN-FXQIFTODSA-N 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 3
- GBYYQVBXFVDJPJ-WLTAIBSBSA-N Gly-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)CN)O GBYYQVBXFVDJPJ-WLTAIBSBSA-N 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 241000880493 Leptailurus serval Species 0.000 description 3
- PXHCFKXNSBJSTQ-KKUMJFAQSA-N Lys-Asn-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N)O PXHCFKXNSBJSTQ-KKUMJFAQSA-N 0.000 description 3
- BQVUABVGYYSDCJ-UHFFFAOYSA-N Nalpha-L-Leucyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-UHFFFAOYSA-N 0.000 description 3
- GNRMAQSIROFNMI-IXOXFDKPSA-N Phe-Thr-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O GNRMAQSIROFNMI-IXOXFDKPSA-N 0.000 description 3
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 3
- JQAWYCUUFIMTHE-WLTAIBSBSA-N Thr-Gly-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JQAWYCUUFIMTHE-WLTAIBSBSA-N 0.000 description 3
- YYLHVUCSTXXKBS-IHRRRGAJSA-N Tyr-Pro-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O YYLHVUCSTXXKBS-IHRRRGAJSA-N 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 108010062796 arginyllysine Proteins 0.000 description 3
- 108010068265 aspartyltyrosine Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 108010015792 glycyllysine Proteins 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 108010077037 tyrosyl-tyrosyl-phenylalanine Proteins 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 2
- JBGSZRYCXBPWGX-BQBZGAKWSA-N Ala-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CCCN=C(N)N JBGSZRYCXBPWGX-BQBZGAKWSA-N 0.000 description 2
- BTRULDJUUVGRNE-DCAQKATOSA-N Ala-Pro-Lys Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O BTRULDJUUVGRNE-DCAQKATOSA-N 0.000 description 2
- CREYEAPXISDKSB-FQPOAREZSA-N Ala-Thr-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CREYEAPXISDKSB-FQPOAREZSA-N 0.000 description 2
- VKKYFICVTYKFIO-CIUDSAMLSA-N Arg-Ala-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N VKKYFICVTYKFIO-CIUDSAMLSA-N 0.000 description 2
- MKJBPDLENBUHQU-CIUDSAMLSA-N Asn-Ser-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O MKJBPDLENBUHQU-CIUDSAMLSA-N 0.000 description 2
- UGXYFDQFLVCDFC-CIUDSAMLSA-N Asn-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O UGXYFDQFLVCDFC-CIUDSAMLSA-N 0.000 description 2
- JBDLMLZNDRLDIX-HJGDQZAQSA-N Asn-Thr-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O JBDLMLZNDRLDIX-HJGDQZAQSA-N 0.000 description 2
- XYBJLTKSGFBLCS-QXEWZRGKSA-N Asp-Arg-Val Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC(O)=O XYBJLTKSGFBLCS-QXEWZRGKSA-N 0.000 description 2
- QNFRBNZGVVKBNJ-PEFMBERDSA-N Asp-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N QNFRBNZGVVKBNJ-PEFMBERDSA-N 0.000 description 2
- MNQMTYSEKZHIDF-GCJQMDKQSA-N Asp-Thr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O MNQMTYSEKZHIDF-GCJQMDKQSA-N 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- NIXHTNJAGGFBAW-CIUDSAMLSA-N Cys-Lys-Ser Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CS)N NIXHTNJAGGFBAW-CIUDSAMLSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- OYTPNWYZORARHL-XHNCKOQMSA-N Gln-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N OYTPNWYZORARHL-XHNCKOQMSA-N 0.000 description 2
- JXFLPKSDLDEOQK-JHEQGTHGSA-N Gln-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O JXFLPKSDLDEOQK-JHEQGTHGSA-N 0.000 description 2
- FQCILXROGNOZON-YUMQZZPRSA-N Gln-Pro-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O FQCILXROGNOZON-YUMQZZPRSA-N 0.000 description 2
- PAQUJCSYVIBPLC-AVGNSLFASA-N Glu-Asp-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PAQUJCSYVIBPLC-AVGNSLFASA-N 0.000 description 2
- RFTVTKBHDXCEEX-WDSKDSINSA-N Glu-Ser-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RFTVTKBHDXCEEX-WDSKDSINSA-N 0.000 description 2
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 2
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 2
- HAOUOFNNJJLVNS-BQBZGAKWSA-N Gly-Pro-Ser Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O HAOUOFNNJJLVNS-BQBZGAKWSA-N 0.000 description 2
- NVTPVQLIZCOJFK-FOHZUACHSA-N Gly-Thr-Asp Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O NVTPVQLIZCOJFK-FOHZUACHSA-N 0.000 description 2
- XHVONGZZVUUORG-WEDXCCLWSA-N Gly-Thr-Lys Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCCN XHVONGZZVUUORG-WEDXCCLWSA-N 0.000 description 2
- 101100519206 Homo sapiens PDCD1 gene Proteins 0.000 description 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 2
- PXKACEXYLPBMAD-JBDRJPRFSA-N Ile-Ser-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PXKACEXYLPBMAD-JBDRJPRFSA-N 0.000 description 2
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 2
- HXWALXSAVBLTPK-NUTKFTJISA-N Leu-Ala-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(C)C)N HXWALXSAVBLTPK-NUTKFTJISA-N 0.000 description 2
- AXZGZMGRBDQTEY-SRVKXCTJSA-N Leu-Gln-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O AXZGZMGRBDQTEY-SRVKXCTJSA-N 0.000 description 2
- CQGSYZCULZMEDE-SRVKXCTJSA-N Leu-Gln-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(O)=O CQGSYZCULZMEDE-SRVKXCTJSA-N 0.000 description 2
- CQGSYZCULZMEDE-UHFFFAOYSA-N Leu-Gln-Pro Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)N1CCCC1C(O)=O CQGSYZCULZMEDE-UHFFFAOYSA-N 0.000 description 2
- FEHQLKKBVJHSEC-SZMVWBNQSA-N Leu-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FEHQLKKBVJHSEC-SZMVWBNQSA-N 0.000 description 2
- FAELBUXXFQLUAX-AJNGGQMLSA-N Leu-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C FAELBUXXFQLUAX-AJNGGQMLSA-N 0.000 description 2
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 2
- SUYRAPCRSCCPAK-VFAJRCTISA-N Leu-Trp-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SUYRAPCRSCCPAK-VFAJRCTISA-N 0.000 description 2
- AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 description 2
- YQFZRHYZLARWDY-IHRRRGAJSA-N Leu-Val-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN YQFZRHYZLARWDY-IHRRRGAJSA-N 0.000 description 2
- FLCMXEFCTLXBTL-DCAQKATOSA-N Lys-Asp-Arg Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N FLCMXEFCTLXBTL-DCAQKATOSA-N 0.000 description 2
- PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- SPSSJSICDYYTQN-HJGDQZAQSA-N Met-Thr-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O SPSSJSICDYYTQN-HJGDQZAQSA-N 0.000 description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 101150087384 PDCD1 gene Proteins 0.000 description 2
- YYKZDTVQHTUKDW-RYUDHWBXSA-N Phe-Gly-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)O)N YYKZDTVQHTUKDW-RYUDHWBXSA-N 0.000 description 2
- BPCLGWHVPVTTFM-QWRGUYRKSA-N Phe-Ser-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)NCC(O)=O BPCLGWHVPVTTFM-QWRGUYRKSA-N 0.000 description 2
- FGWUALWGCZJQDJ-URLPEUOOSA-N Phe-Thr-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FGWUALWGCZJQDJ-URLPEUOOSA-N 0.000 description 2
- KLYYKKGCPOGDPE-OEAJRASXSA-N Phe-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O KLYYKKGCPOGDPE-OEAJRASXSA-N 0.000 description 2
- GOMUXSCOIWIJFP-GUBZILKMSA-N Pro-Ser-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GOMUXSCOIWIJFP-GUBZILKMSA-N 0.000 description 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 2
- QEDMOZUJTGEIBF-FXQIFTODSA-N Ser-Arg-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O QEDMOZUJTGEIBF-FXQIFTODSA-N 0.000 description 2
- FMDHKPRACUXATF-ACZMJKKPSA-N Ser-Gln-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O FMDHKPRACUXATF-ACZMJKKPSA-N 0.000 description 2
- SQBLRDDJTUJDMV-ACZMJKKPSA-N Ser-Glu-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O SQBLRDDJTUJDMV-ACZMJKKPSA-N 0.000 description 2
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 2
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 2
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 2
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 2
- PQEQXWRVHQAAKS-SRVKXCTJSA-N Ser-Tyr-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)N)CC1=CC=C(O)C=C1 PQEQXWRVHQAAKS-SRVKXCTJSA-N 0.000 description 2
- UBTNVMGPMYDYIU-HJPIBITLSA-N Ser-Tyr-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O UBTNVMGPMYDYIU-HJPIBITLSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- LKEKWDJCJSPXNI-IRIUXVKKSA-N Thr-Glu-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 LKEKWDJCJSPXNI-IRIUXVKKSA-N 0.000 description 2
- GXUWHVZYDAHFSV-FLBSBUHZSA-N Thr-Ile-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GXUWHVZYDAHFSV-FLBSBUHZSA-N 0.000 description 2
- RQLNEFOBQAVGSY-WDSOQIARSA-N Trp-Met-Leu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O RQLNEFOBQAVGSY-WDSOQIARSA-N 0.000 description 2
- MBLJBGZWLHTJBH-SZMVWBNQSA-N Trp-Val-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 MBLJBGZWLHTJBH-SZMVWBNQSA-N 0.000 description 2
- FFCRCJZJARTYCG-KKUMJFAQSA-N Tyr-Cys-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)O)N)O FFCRCJZJARTYCG-KKUMJFAQSA-N 0.000 description 2
- QUILOGWWLXMSAT-IHRRRGAJSA-N Tyr-Gln-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O QUILOGWWLXMSAT-IHRRRGAJSA-N 0.000 description 2
- LMKKMCGTDANZTR-BZSNNMDCSA-N Tyr-Phe-Asp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LMKKMCGTDANZTR-BZSNNMDCSA-N 0.000 description 2
- ZYVAAYAOTVJBSS-GMVOTWDCSA-N Tyr-Trp-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C)C(O)=O ZYVAAYAOTVJBSS-GMVOTWDCSA-N 0.000 description 2
- NUQZCPSZHGIYTA-HKUYNNGSSA-N Tyr-Trp-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N NUQZCPSZHGIYTA-HKUYNNGSSA-N 0.000 description 2
- WKWJJQZZZBBWKV-JYJNAYRXSA-N Val-Arg-Tyr Chemical compound NC(N)=NCCC[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 WKWJJQZZZBBWKV-JYJNAYRXSA-N 0.000 description 2
- VCAWFLIWYNMHQP-UKJIMTQDSA-N Val-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)N VCAWFLIWYNMHQP-UKJIMTQDSA-N 0.000 description 2
- OWFGFHQMSBTKLX-UFYCRDLUSA-N Val-Tyr-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N OWFGFHQMSBTKLX-UFYCRDLUSA-N 0.000 description 2
- 108010081404 acein-2 Proteins 0.000 description 2
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 2
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 2
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 108010013835 arginine glutamate Proteins 0.000 description 2
- 108010008355 arginyl-glutamine Proteins 0.000 description 2
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 108010064235 lysylglycine Proteins 0.000 description 2
- 238000007885 magnetic separation Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 208000021039 metastatic melanoma Diseases 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 2
- 108010070643 prolylglutamic acid Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 108010044292 tryptophyltyrosine Proteins 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 108010035534 tyrosyl-leucyl-alanine Proteins 0.000 description 2
- 108010003137 tyrosyltyrosine Proteins 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- PIPTUBPKYFRLCP-NHCYSSNCSA-N Ala-Ala-Phe Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PIPTUBPKYFRLCP-NHCYSSNCSA-N 0.000 description 1
- CXRCVCURMBFFOL-FXQIFTODSA-N Ala-Ala-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CXRCVCURMBFFOL-FXQIFTODSA-N 0.000 description 1
- KUDREHRZRIVKHS-UWJYBYFXSA-N Ala-Asp-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KUDREHRZRIVKHS-UWJYBYFXSA-N 0.000 description 1
- SFNFGFDRYJKZKN-XQXXSGGOSA-N Ala-Gln-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)N)O SFNFGFDRYJKZKN-XQXXSGGOSA-N 0.000 description 1
- MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 1
- MDNAVFBZPROEHO-UHFFFAOYSA-N Ala-Lys-Val Natural products CC(C)C(C(O)=O)NC(=O)C(NC(=O)C(C)N)CCCCN MDNAVFBZPROEHO-UHFFFAOYSA-N 0.000 description 1
- 108010011667 Ala-Phe-Ala Proteins 0.000 description 1
- DYJJJCHDHLEFDW-FXQIFTODSA-N Ala-Pro-Cys Chemical compound C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)O)N DYJJJCHDHLEFDW-FXQIFTODSA-N 0.000 description 1
- IORKCNUBHNIMKY-CIUDSAMLSA-N Ala-Pro-Glu Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O IORKCNUBHNIMKY-CIUDSAMLSA-N 0.000 description 1
- YJHKTAMKPGFJCT-NRPADANISA-N Ala-Val-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O YJHKTAMKPGFJCT-NRPADANISA-N 0.000 description 1
- PNQWAUXQDBIJDY-GUBZILKMSA-N Arg-Glu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PNQWAUXQDBIJDY-GUBZILKMSA-N 0.000 description 1
- XRNXPIGJPQHCPC-RCWTZXSCSA-N Arg-Thr-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)O)C(O)=O XRNXPIGJPQHCPC-RCWTZXSCSA-N 0.000 description 1
- ZUVMUOOHJYNJPP-XIRDDKMYSA-N Arg-Trp-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZUVMUOOHJYNJPP-XIRDDKMYSA-N 0.000 description 1
- UVTGNSWSRSCPLP-UHFFFAOYSA-N Arg-Tyr Natural products NC(CCNC(=N)N)C(=O)NC(Cc1ccc(O)cc1)C(=O)O UVTGNSWSRSCPLP-UHFFFAOYSA-N 0.000 description 1
- XYOVHPDDWCEUDY-CIUDSAMLSA-N Asn-Ala-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O XYOVHPDDWCEUDY-CIUDSAMLSA-N 0.000 description 1
- GXMSVVBIAMWMKO-BQBZGAKWSA-N Asn-Arg-Gly Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CCCN=C(N)N GXMSVVBIAMWMKO-BQBZGAKWSA-N 0.000 description 1
- WONGRTVAMHFGBE-WDSKDSINSA-N Asn-Gly-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N WONGRTVAMHFGBE-WDSKDSINSA-N 0.000 description 1
- LGCVSPFCFXWUEY-IHPCNDPISA-N Asn-Trp-Tyr Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N LGCVSPFCFXWUEY-IHPCNDPISA-N 0.000 description 1
- SNDBKTFJWVEVPO-WHFBIAKZSA-N Asp-Gly-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(O)=O SNDBKTFJWVEVPO-WHFBIAKZSA-N 0.000 description 1
- UZFHNLYQWMGUHU-DCAQKATOSA-N Asp-Lys-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UZFHNLYQWMGUHU-DCAQKATOSA-N 0.000 description 1
- GKWFMNNNYZHJHV-SRVKXCTJSA-N Asp-Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC(O)=O GKWFMNNNYZHJHV-SRVKXCTJSA-N 0.000 description 1
- DPNWSMBUYCLEDG-CIUDSAMLSA-N Asp-Lys-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O DPNWSMBUYCLEDG-CIUDSAMLSA-N 0.000 description 1
- SQIARYGNVQWOSB-BZSNNMDCSA-N Asp-Tyr-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SQIARYGNVQWOSB-BZSNNMDCSA-N 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 101100421200 Caenorhabditis elegans sep-1 gene Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- VIRYODQIWJNWNU-NRPADANISA-N Cys-Glu-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CS)N VIRYODQIWJNWNU-NRPADANISA-N 0.000 description 1
- KSMSFCBQBQPFAD-GUBZILKMSA-N Cys-Pro-Pro Chemical compound SC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 KSMSFCBQBQPFAD-GUBZILKMSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- DHNWZLGBTPUTQQ-QEJZJMRPSA-N Gln-Asp-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)N DHNWZLGBTPUTQQ-QEJZJMRPSA-N 0.000 description 1
- IULKWYSYZSURJK-AVGNSLFASA-N Gln-Leu-Lys Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O IULKWYSYZSURJK-AVGNSLFASA-N 0.000 description 1
- AQPZYBSRDRZBAG-AVGNSLFASA-N Gln-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N AQPZYBSRDRZBAG-AVGNSLFASA-N 0.000 description 1
- LPIKVBWNNVFHCQ-GUBZILKMSA-N Gln-Ser-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O LPIKVBWNNVFHCQ-GUBZILKMSA-N 0.000 description 1
- FITIQFSXXBKFFM-NRPADANISA-N Gln-Val-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O FITIQFSXXBKFFM-NRPADANISA-N 0.000 description 1
- JJKKWYQVHRUSDG-GUBZILKMSA-N Glu-Ala-Lys Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O JJKKWYQVHRUSDG-GUBZILKMSA-N 0.000 description 1
- GLWXKFRTOHKGIT-ACZMJKKPSA-N Glu-Asn-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O GLWXKFRTOHKGIT-ACZMJKKPSA-N 0.000 description 1
- CKOFNWCLWRYUHK-XHNCKOQMSA-N Glu-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)N)C(=O)O CKOFNWCLWRYUHK-XHNCKOQMSA-N 0.000 description 1
- CLROYXHHUZELFX-FXQIFTODSA-N Glu-Gln-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O CLROYXHHUZELFX-FXQIFTODSA-N 0.000 description 1
- KASDBWKLWJKTLJ-GUBZILKMSA-N Glu-Glu-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O KASDBWKLWJKTLJ-GUBZILKMSA-N 0.000 description 1
- QDMVXRNLOPTPIE-WDCWCFNPSA-N Glu-Lys-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QDMVXRNLOPTPIE-WDCWCFNPSA-N 0.000 description 1
- VSVZIEVNUYDAFR-YUMQZZPRSA-N Gly-Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN VSVZIEVNUYDAFR-YUMQZZPRSA-N 0.000 description 1
- GRIRDMVMJJDZKV-RCOVLWMOSA-N Gly-Asn-Val Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O GRIRDMVMJJDZKV-RCOVLWMOSA-N 0.000 description 1
- UUYBFNKHOCJCHT-VHSXEESVSA-N Gly-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN UUYBFNKHOCJCHT-VHSXEESVSA-N 0.000 description 1
- NNCSJUBVFBDDLC-YUMQZZPRSA-N Gly-Leu-Ser Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O NNCSJUBVFBDDLC-YUMQZZPRSA-N 0.000 description 1
- GJHWILMUOANXTG-WPRPVWTQSA-N Gly-Val-Arg Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GJHWILMUOANXTG-WPRPVWTQSA-N 0.000 description 1
- MAABHGXCIBEYQR-XVYDVKMFSA-N His-Asn-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC1=CN=CN1)N MAABHGXCIBEYQR-XVYDVKMFSA-N 0.000 description 1
- HIAHVKLTHNOENC-HGNGGELXSA-N His-Glu-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O HIAHVKLTHNOENC-HGNGGELXSA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- QQFSKBMCAKWHLG-UHFFFAOYSA-N Ile-Phe-Pro-Pro Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(NC(=O)C(N)C(C)CC)CC1=CC=CC=C1 QQFSKBMCAKWHLG-UHFFFAOYSA-N 0.000 description 1
- JHNJNTMTZHEDLJ-NAKRPEOUSA-N Ile-Ser-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O JHNJNTMTZHEDLJ-NAKRPEOUSA-N 0.000 description 1
- VGSPNSSCMOHRRR-BJDJZHNGSA-N Ile-Ser-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N VGSPNSSCMOHRRR-BJDJZHNGSA-N 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 1
- DBVWMYGBVFCRBE-CIUDSAMLSA-N Leu-Asn-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O DBVWMYGBVFCRBE-CIUDSAMLSA-N 0.000 description 1
- OIARJGNVARWKFP-YUMQZZPRSA-N Leu-Asn-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O OIARJGNVARWKFP-YUMQZZPRSA-N 0.000 description 1
- APFJUBGRZGMQFF-QWRGUYRKSA-N Leu-Gly-Lys Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN APFJUBGRZGMQFF-QWRGUYRKSA-N 0.000 description 1
- HYMLKESRWLZDBR-WEDXCCLWSA-N Leu-Gly-Thr Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O HYMLKESRWLZDBR-WEDXCCLWSA-N 0.000 description 1
- BTNXKBVLWJBTNR-SRVKXCTJSA-N Leu-His-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(O)=O BTNXKBVLWJBTNR-SRVKXCTJSA-N 0.000 description 1
- AMSSKPUHBUQBOQ-SRVKXCTJSA-N Leu-Ser-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N AMSSKPUHBUQBOQ-SRVKXCTJSA-N 0.000 description 1
- BRTVHXHCUSXYRI-CIUDSAMLSA-N Leu-Ser-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O BRTVHXHCUSXYRI-CIUDSAMLSA-N 0.000 description 1
- LINKCQUOMUDLKN-KATARQTJSA-N Leu-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(C)C)N)O LINKCQUOMUDLKN-KATARQTJSA-N 0.000 description 1
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- MWVUEPNEPWMFBD-SRVKXCTJSA-N Lys-Cys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CCCCN MWVUEPNEPWMFBD-SRVKXCTJSA-N 0.000 description 1
- NNCDAORZCMPZPX-GUBZILKMSA-N Lys-Gln-Ser Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N NNCDAORZCMPZPX-GUBZILKMSA-N 0.000 description 1
- ODUQLUADRKMHOZ-JYJNAYRXSA-N Lys-Glu-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)N)O ODUQLUADRKMHOZ-JYJNAYRXSA-N 0.000 description 1
- XNKDCYABMBBEKN-IUCAKERBSA-N Lys-Gly-Gln Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O XNKDCYABMBBEKN-IUCAKERBSA-N 0.000 description 1
- FGMHXLULNHTPID-KKUMJFAQSA-N Lys-His-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 FGMHXLULNHTPID-KKUMJFAQSA-N 0.000 description 1
- YTJFXEDRUOQGSP-DCAQKATOSA-N Lys-Pro-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O YTJFXEDRUOQGSP-DCAQKATOSA-N 0.000 description 1
- IOQWIOPSKJOEKI-SRVKXCTJSA-N Lys-Ser-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IOQWIOPSKJOEKI-SRVKXCTJSA-N 0.000 description 1
- SQXZLVXQXWILKW-KKUMJFAQSA-N Lys-Ser-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SQXZLVXQXWILKW-KKUMJFAQSA-N 0.000 description 1
- DIBZLYZXTSVGLN-CIUDSAMLSA-N Lys-Ser-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O DIBZLYZXTSVGLN-CIUDSAMLSA-N 0.000 description 1
- YKBSXQFZWFXFIB-VOAKCMCISA-N Lys-Thr-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCCN)C(O)=O YKBSXQFZWFXFIB-VOAKCMCISA-N 0.000 description 1
- YFQSSOAGMZGXFT-MEYUZBJRSA-N Lys-Thr-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O YFQSSOAGMZGXFT-MEYUZBJRSA-N 0.000 description 1
- RQILLQOQXLZTCK-KBPBESRZSA-N Lys-Tyr-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O RQILLQOQXLZTCK-KBPBESRZSA-N 0.000 description 1
- QLFAPXUXEBAWEK-NHCYSSNCSA-N Lys-Val-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O QLFAPXUXEBAWEK-NHCYSSNCSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- SMFGCTXUBWEPKM-KBPBESRZSA-N Phe-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 SMFGCTXUBWEPKM-KBPBESRZSA-N 0.000 description 1
- JDMKQHSHKJHAHR-UHFFFAOYSA-N Phe-Phe-Leu-Tyr Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)CC1=CC=CC=C1 JDMKQHSHKJHAHR-UHFFFAOYSA-N 0.000 description 1
- JLLJTMHNXQTMCK-UBHSHLNASA-N Phe-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=CC=C1 JLLJTMHNXQTMCK-UBHSHLNASA-N 0.000 description 1
- IIEOLPMQYRBZCN-SRVKXCTJSA-N Phe-Ser-Cys Chemical compound N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O IIEOLPMQYRBZCN-SRVKXCTJSA-N 0.000 description 1
- SJRQWEDYTKYHHL-SLFFLAALSA-N Phe-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=CC=C3)N)C(=O)O SJRQWEDYTKYHHL-SLFFLAALSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- IHCXPSYCHXFXKT-DCAQKATOSA-N Pro-Arg-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O IHCXPSYCHXFXKT-DCAQKATOSA-N 0.000 description 1
- TUYWCHPXKQTISF-LPEHRKFASA-N Pro-Cys-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CS)C(=O)N2CCC[C@@H]2C(=O)O TUYWCHPXKQTISF-LPEHRKFASA-N 0.000 description 1
- UAYHMOIGIQZLFR-NHCYSSNCSA-N Pro-Gln-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O UAYHMOIGIQZLFR-NHCYSSNCSA-N 0.000 description 1
- LGSANCBHSMDFDY-GARJFASQSA-N Pro-Glu-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)O)C(=O)N2CCC[C@@H]2C(=O)O LGSANCBHSMDFDY-GARJFASQSA-N 0.000 description 1
- ZLXKLMHAMDENIO-DCAQKATOSA-N Pro-Lys-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLXKLMHAMDENIO-DCAQKATOSA-N 0.000 description 1
- HWLKHNDRXWTFTN-GUBZILKMSA-N Pro-Pro-Cys Chemical compound C1C[C@H](NC1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CS)C(=O)O HWLKHNDRXWTFTN-GUBZILKMSA-N 0.000 description 1
- PCWLNNZTBJTZRN-AVGNSLFASA-N Pro-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 PCWLNNZTBJTZRN-AVGNSLFASA-N 0.000 description 1
- FDMKYQQYJKYCLV-GUBZILKMSA-N Pro-Pro-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 FDMKYQQYJKYCLV-GUBZILKMSA-N 0.000 description 1
- MKGIILKDUGDRRO-FXQIFTODSA-N Pro-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 MKGIILKDUGDRRO-FXQIFTODSA-N 0.000 description 1
- YDTUEBLEAVANFH-RCWTZXSCSA-N Pro-Val-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 YDTUEBLEAVANFH-RCWTZXSCSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- QVOGDCQNGLBNCR-FXQIFTODSA-N Ser-Arg-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O QVOGDCQNGLBNCR-FXQIFTODSA-N 0.000 description 1
- VGNYHOBZJKWRGI-CIUDSAMLSA-N Ser-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO VGNYHOBZJKWRGI-CIUDSAMLSA-N 0.000 description 1
- FTVRVZNYIYWJGB-ACZMJKKPSA-N Ser-Asp-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O FTVRVZNYIYWJGB-ACZMJKKPSA-N 0.000 description 1
- QPFJSHSJFIYDJZ-GHCJXIJMSA-N Ser-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CO QPFJSHSJFIYDJZ-GHCJXIJMSA-N 0.000 description 1
- ZOHGLPQGEHSLPD-FXQIFTODSA-N Ser-Gln-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZOHGLPQGEHSLPD-FXQIFTODSA-N 0.000 description 1
- BPMRXBZYPGYPJN-WHFBIAKZSA-N Ser-Gly-Asn Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O BPMRXBZYPGYPJN-WHFBIAKZSA-N 0.000 description 1
- GZFAWAQTEYDKII-YUMQZZPRSA-N Ser-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO GZFAWAQTEYDKII-YUMQZZPRSA-N 0.000 description 1
- SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 1
- PPNPDKGQRFSCAC-CIUDSAMLSA-N Ser-Lys-Asp Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(O)=O)C(O)=O PPNPDKGQRFSCAC-CIUDSAMLSA-N 0.000 description 1
- HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 description 1
- JCLAFVNDBJMLBC-JBDRJPRFSA-N Ser-Ser-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JCLAFVNDBJMLBC-JBDRJPRFSA-N 0.000 description 1
- VGQVAVQWKJLIRM-FXQIFTODSA-N Ser-Ser-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O VGQVAVQWKJLIRM-FXQIFTODSA-N 0.000 description 1
- XJDMUQCLVSCRSJ-VZFHVOOUSA-N Ser-Thr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O XJDMUQCLVSCRSJ-VZFHVOOUSA-N 0.000 description 1
- PCJLFYBAQZQOFE-KATARQTJSA-N Ser-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N)O PCJLFYBAQZQOFE-KATARQTJSA-N 0.000 description 1
- ZKOKTQPHFMRSJP-YJRXYDGGSA-N Ser-Thr-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZKOKTQPHFMRSJP-YJRXYDGGSA-N 0.000 description 1
- AXKJPUBALUNJEO-UBHSHLNASA-N Ser-Trp-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(O)=O AXKJPUBALUNJEO-UBHSHLNASA-N 0.000 description 1
- RCOUFINCYASMDN-GUBZILKMSA-N Ser-Val-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCSC)C(O)=O RCOUFINCYASMDN-GUBZILKMSA-N 0.000 description 1
- HNDMFDBQXYZSRM-IHRRRGAJSA-N Ser-Val-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HNDMFDBQXYZSRM-IHRRRGAJSA-N 0.000 description 1
- SIEBDTCABMZCLF-XGEHTFHBSA-N Ser-Val-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SIEBDTCABMZCLF-XGEHTFHBSA-N 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- UKBSDLHIKIXJKH-HJGDQZAQSA-N Thr-Arg-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O UKBSDLHIKIXJKH-HJGDQZAQSA-N 0.000 description 1
- ODSAPYVQSLDRSR-LKXGYXEUSA-N Thr-Cys-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O ODSAPYVQSLDRSR-LKXGYXEUSA-N 0.000 description 1
- DSLHSTIUAPKERR-XGEHTFHBSA-N Thr-Cys-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O DSLHSTIUAPKERR-XGEHTFHBSA-N 0.000 description 1
- CYVQBKQYQGEELV-NKIYYHGXSA-N Thr-His-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O CYVQBKQYQGEELV-NKIYYHGXSA-N 0.000 description 1
- FIFDDJFLNVAVMS-RHYQMDGZSA-N Thr-Leu-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(O)=O FIFDDJFLNVAVMS-RHYQMDGZSA-N 0.000 description 1
- VRUFCJZQDACGLH-UVOCVTCTSA-N Thr-Leu-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VRUFCJZQDACGLH-UVOCVTCTSA-N 0.000 description 1
- BDGBHYCAZJPLHX-HJGDQZAQSA-N Thr-Lys-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O BDGBHYCAZJPLHX-HJGDQZAQSA-N 0.000 description 1
- DXPURPNJDFCKKO-RHYQMDGZSA-N Thr-Lys-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)[C@@H](C)O)C(O)=O DXPURPNJDFCKKO-RHYQMDGZSA-N 0.000 description 1
- XKWABWFMQXMUMT-HJGDQZAQSA-N Thr-Pro-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O XKWABWFMQXMUMT-HJGDQZAQSA-N 0.000 description 1
- MROIJTGJGIDEEJ-RCWTZXSCSA-N Thr-Pro-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 MROIJTGJGIDEEJ-RCWTZXSCSA-N 0.000 description 1
- XHWCDRUPDNSDAZ-XKBZYTNZSA-N Thr-Ser-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N)O XHWCDRUPDNSDAZ-XKBZYTNZSA-N 0.000 description 1
- SGAOHNPSEPVAFP-ZDLURKLDSA-N Thr-Ser-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SGAOHNPSEPVAFP-ZDLURKLDSA-N 0.000 description 1
- CYCGARJWIQWPQM-YJRXYDGGSA-N Thr-Tyr-Ser Chemical compound C[C@@H](O)[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CO)C([O-])=O)CC1=CC=C(O)C=C1 CYCGARJWIQWPQM-YJRXYDGGSA-N 0.000 description 1
- AVYVKJMBNLPWRX-WFBYXXMGSA-N Trp-Ala-Ser Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O)=CNC2=C1 AVYVKJMBNLPWRX-WFBYXXMGSA-N 0.000 description 1
- UDCHKDYNMRJYMI-QEJZJMRPSA-N Trp-Glu-Ser Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O UDCHKDYNMRJYMI-QEJZJMRPSA-N 0.000 description 1
- AYHSJESDFKREAR-KKUMJFAQSA-N Tyr-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AYHSJESDFKREAR-KKUMJFAQSA-N 0.000 description 1
- SINRIKQYQJRGDQ-MEYUZBJRSA-N Tyr-Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 SINRIKQYQJRGDQ-MEYUZBJRSA-N 0.000 description 1
- AUZADXNWQMBZOO-JYJNAYRXSA-N Tyr-Pro-Arg Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C1=CC=C(O)C=C1 AUZADXNWQMBZOO-JYJNAYRXSA-N 0.000 description 1
- RWOKVQUCENPXGE-IHRRRGAJSA-N Tyr-Ser-Arg Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O RWOKVQUCENPXGE-IHRRRGAJSA-N 0.000 description 1
- MQGGXGKQSVEQHR-KKUMJFAQSA-N Tyr-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MQGGXGKQSVEQHR-KKUMJFAQSA-N 0.000 description 1
- RIVVDNTUSRVTQT-IRIUXVKKSA-N Tyr-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O RIVVDNTUSRVTQT-IRIUXVKKSA-N 0.000 description 1
- PWKMJDQXKCENMF-MEYUZBJRSA-N Tyr-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O PWKMJDQXKCENMF-MEYUZBJRSA-N 0.000 description 1
- TYGHOWWWMTWVKM-HJOGWXRNSA-N Tyr-Tyr-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 TYGHOWWWMTWVKM-HJOGWXRNSA-N 0.000 description 1
- QHDXUYOYTPWCSK-RCOVLWMOSA-N Val-Asp-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O)N QHDXUYOYTPWCSK-RCOVLWMOSA-N 0.000 description 1
- ZQGPWORGSNRQLN-NHCYSSNCSA-N Val-Asp-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N ZQGPWORGSNRQLN-NHCYSSNCSA-N 0.000 description 1
- LHADRQBREKTRLR-DCAQKATOSA-N Val-Cys-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)N LHADRQBREKTRLR-DCAQKATOSA-N 0.000 description 1
- OXVPMZVGCAPFIG-BQFCYCMXSA-N Val-Gln-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N OXVPMZVGCAPFIG-BQFCYCMXSA-N 0.000 description 1
- OQWNEUXPKHIEJO-NRPADANISA-N Val-Glu-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)O)N OQWNEUXPKHIEJO-NRPADANISA-N 0.000 description 1
- UEHRGZCNLSWGHK-DLOVCJGASA-N Val-Glu-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O UEHRGZCNLSWGHK-DLOVCJGASA-N 0.000 description 1
- ZIGZPYJXIWLQFC-QTKMDUPCSA-N Val-His-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](C(C)C)N)O ZIGZPYJXIWLQFC-QTKMDUPCSA-N 0.000 description 1
- HGJRMXOWUWVUOA-GVXVVHGQSA-N Val-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N HGJRMXOWUWVUOA-GVXVVHGQSA-N 0.000 description 1
- XTDDIVQWDXMRJL-IHRRRGAJSA-N Val-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C(C)C)N XTDDIVQWDXMRJL-IHRRRGAJSA-N 0.000 description 1
- SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 1
- HJSLDXZAZGFPDK-ULQDDVLXSA-N Val-Phe-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](C(C)C)N HJSLDXZAZGFPDK-ULQDDVLXSA-N 0.000 description 1
- VCIYTVOBLZHFSC-XHSDSOJGSA-N Val-Phe-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N VCIYTVOBLZHFSC-XHSDSOJGSA-N 0.000 description 1
- RYHUIHUOYRNNIE-NRPADANISA-N Val-Ser-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N RYHUIHUOYRNNIE-NRPADANISA-N 0.000 description 1
- QPJSIBAOZBVELU-BPNCWPANSA-N Val-Tyr-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C(C)C)N QPJSIBAOZBVELU-BPNCWPANSA-N 0.000 description 1
- ZLNYBMWGPOKSLW-LSJOCFKGSA-N Val-Val-Asp Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLNYBMWGPOKSLW-LSJOCFKGSA-N 0.000 description 1
- LLJLBRRXKZTTRD-GUBZILKMSA-N Val-Val-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)O)N LLJLBRRXKZTTRD-GUBZILKMSA-N 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 1
- 230000001188 anti-phage Effects 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 238000011398 antitumor immunotherapy Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 description 1
- 108010009111 arginyl-glycyl-glutamic acid Proteins 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 206010005084 bladder transitional cell carcinoma Diseases 0.000 description 1
- 201000001528 bladder urothelial carcinoma Diseases 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 108010060199 cysteinylproline Proteins 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 108010078144 glutaminyl-glycine Proteins 0.000 description 1
- 108010013768 glutamyl-aspartyl-proline Proteins 0.000 description 1
- 108010000434 glycyl-alanyl-leucine Proteins 0.000 description 1
- 108010050475 glycyl-leucyl-tyrosine Proteins 0.000 description 1
- 108010077515 glycylproline Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000048362 human PDCD1 Human genes 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 108010053037 kyotorphin Proteins 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 1
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 108010024654 phenylalanyl-prolyl-alanine Proteins 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108010090894 prolylleucine Proteins 0.000 description 1
- 108010053725 prolylvaline Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 108010069117 seryl-lysyl-aspartic acid Proteins 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 description 1
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 108010071097 threonyl-lysyl-proline Proteins 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 108010080629 tryptophan-leucine Proteins 0.000 description 1
- 108010079202 tyrosyl-alanyl-cysteine Proteins 0.000 description 1
- 108010051110 tyrosyl-lysine Proteins 0.000 description 1
- 108010071635 tyrosyl-prolyl-arginine Proteins 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 108010027345 wheylin-1 peptide Proteins 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
Abstract
A kind of antibody screening method that epitope is special, it is low to solve the problems, such as to have in screening of phage antibody library technology medicative functional antibodies screening efficiency, include the steps that being screened with function epitope peptide and living cells screens;It additionally provides and screens a kind of phage displaying antibody library complete anti-PD-1 monoclonal antibody of source of people obtained with this method, for specific functional epitope, PD-1 and the combination of its ligand can effectively be blocked, and have the characteristics that affinity is high, EC50 is low, therapeutic effect can be generated to animal model under low dosage.The present invention substantially increases the screening efficiency of functional antibodies, and provides a kind of immunotherapy medicaments of potential safer economy for malignant tumour, immunological diseases patient.
Description
Technical field
The invention belongs to biomedicine fields, and in particular to a kind of antibody screening method that epitope is special and be screened
Antibody.
Background technique
" immunologic escape " of cancer cell is considered as the main mechanism of tumorigenesis and anti-medicine.Tumour can be by straight
It connects or inhibits the signal of T cell come the removing of protecting oneself to escape immune system indirectly.The immunologic test point therapy of tumour
(immune chenkpoint therapy) is a kind of by a series of approach regulatory T-cells such as co-suppression or costimulatory signals
Activity improves the treatment method of anti-tumor immune response.
PD-1(apoptosis albumen 1, full name in English Programmed Cell Death Protein 1, also referred to as
It is one for a kind of cell surface receptor that CD279) is in the T cell and pre B cell (pro-B cells) for be expressed in activation
Immunologic test point has negative regulation effect to immune system, promotes self tolerance by inhibiting T cell inflammatory activities, it is more specific and
Speech, by promoting in lymph node, (Treg is also inhibition T to PD-1 for the apoptosis of T cells with antigenic specificity and reduction modulating T cell
Cell) the double mechanism of apoptosis prevent the generation of autoimmunity.
PD-1 is encoded by PDCD1 gene, 288 amino acid of overall length, wherein before N-terminal 20 amino acid be signal peptide, at
Excision after ripe, the 21-170 amino acid are extracellular fragment, and the 171-191 amino acid is transmembrane region, the 192-288 amino acid
For intracellular tail.
PD-1 can be with 2 kinds of ligand bindings --- B7 family member PD-L1 and PD-L2.On mouse, PD-L1 wide expression
On a variety of organs such as Yu Xin, lung, thymus gland, spleen, kidney and almost all of mouse tumor cell system, and in a variety of human tumors
High expression on cell;And the expression of PD-L2 is more limited to, mainly Dendritic Cells and a small number of tumor cell lines.Therefore, PD-1
And its ligand PD-L1 becomes the target spot of anti-tumor immunotherapy.
Existing 2 anti-PD-1 target therapeutic agents go through to list at present, are Opdivo(common name Nivolumab respectively)
With Keytruda(common name Pembrolizumab), the approved indication of Opdivo includes unresectable or metastatic
Melanoma and metastatic squamous non-small cell lung cancer, the approved indication of Keytruda have unresectable or metastatic
Melanoma and non-small cell lung cancer, head and neck squamous cell carcinoma, hodgkin lymphoma classical type, bladder transitional cell carcinoma, microsatellite
High unstability cancer etc..
According to the clinical test results that U.S. FDA package insert discloses, Opdivo treats 120 at one and can not cut off
Or in the clinical test of metastasis melanin tumor patient objective remission rate (ORR) be 32%(38 people/120 people), including 4 completely
Alleviate (CR) and the patient of (PR) is alleviated in 34 parts;In another 117 metastatic squamous Patients with Non-small-cell Lung for the treatment of
Clinical test in objective remission rate be 15%(17 people/117 people).Keytruda can not be cut off at one 834 or metastatic is black
Random controls that melanoma patient participates in, opening, in multi-center clinical trial, two test groups (receive various dose respectively
Keytruda treatment) ORR be respectively every three weeks administration 10mg/kg of 33%() and 34%(10mg/kg is administered every two weeks), wherein CR
Rate is respectively that 6%, 5%, PR rate is respectively 27%, 29%, and the ORR of control group (anti-CTLA-4 monoclonal antibody Ipilimumab treatment) is
12%;In the random controls of another 305 Metastatic Nsclc patient participation, opening, multi-center clinical trial,
The ORR of test group (Keytruda treatment) is 45%(wherein CR4%, PR41%), and the ORR of control group (chemotherapy) be 28%(wherein
CR1%, PR27%).Although the above research as can be seen that compared with chemotherapy and anti-CTLA-4 are treated, Opdivo and Keytruda's
Anti- PD-1 treatment is obviously improved on objective remission rate ORR, however the patient for still only having one third or so is benefited, and one
Most patients cannot obtain disease amelioration.
The validity of anti-PD-1 Antybody therapy malignant tumour is mainly related to the blocking effect in conjunction with PD-1/PD-L1 with it.
Combination epitope and its polymorphism of the anti-PD-1 antibody on PD-1 molecule, and the affinity combined are (general normal with balance dissociation
Number KD values indicate), many factors such as specificity can all influence the barrier effect that anti-PD-1 antibody combines PD-1/PD-L1.
Phage displaying antibody library is a kind of technology of high flux screening antibody, at present in the industry often with the target of recombinant expression point
Sub- extracellular region is as target antigen screening antibodies library.The extracellular region of these target molecules only has one or several generally by 5-15 amino
Sour composition function epitope is responsible for and ligand binding, therefore only just has patent medicine potentiality for the antibody of specific function epitope.And
For the extracellular domain fragment of recombinant expression for screening of phage antibody library in addition to the functional domain for playing biological function individually, there are also a large amount of
Dominant antigen epitope, therefore screen the antibody majority obtained and only combine activity, but do not block in its biological function
And activity, there is no patent medicine potentiality, need to be tested using a large amount of function assessment and Epitope Identification work can just be selected and make with treatment
Functional antibodies.Also there is the case using the epitope peptide screening antibodies library synthesized, however due to the epitope peptide and day of synthesis
The epitope of right conformation there may be difference, can with the antibody in conjunction with epitope peptide it is different surely with the antigen table of liver cell surface
Position combines.In short, existing screening of phage antibody library technology is low to the functional antibodies hit rate for having the epitope of patent medicine potentiality special, seriously
The efficiency for affecting high flux screening increases the cost of later period clone identification.
Summary of the invention
The present invention provides a kind of method of high frequency zone antibody library, existing screening of phage antibody library technology is able to solve to having into
The low problem of the special functional antibodies hit rate of the epitope of medicine potentiality.This screening technique is used the present invention also provides a kind of
The anti-PD-1 monoclonal antibody obtained, and Nivolumab, Pembrolizumab possess different combination epitopes, and affinity
It is high, specific good, it can solve the problems, such as that some patientss are invalid to existing anti-PD-1 treatment.
Technical scheme is as follows:
A kind of screening technique for the functional antibodies that epitope is special, including following two screening step:
Step 1: for the epitope with biological function, synthetic antigen epitope peptide is simultaneously coupled on solid-phase media, from biting
First run screening is carried out in phage display antibody library, is obtained and the bacteriophage of epitope peptide specific binding and amplification;
Step 2: obtaining or building is in the cell strain of cell surface height expression purpose antigen, is obtained with living cells from first run screening
Bacteriophage in further bacteriophage of the screening in conjunction with cell surface antigen, to prepare functional antibodies.
It, can be Step 1: the sequential Cycle Screening 2-5 wheel of step 2, be carried out by the technical program for the specificity of enhancing screening
The techniqueflow chart of antibody screening can refer to attached drawing 1.
In step 1, the amino acid sequence of the epitope with biological function can be lacked according to crystallization of protein, segment
Mistake/point mutation obtains the methods of the affinity analysis of ligand/receptor, software prediction, the epitope peptide be by 10 to
The cyclic peptide of 15 amino acid composition, the Amino acid profile of cyclic peptide meet the following conditions:
(1) have in cyclic peptide and only 1 cysteine, cyclic peptide passes through the sulfydryl covalent coupling of the cysteine to solid-phase media
On;
(2) respectively there are one section of link peptide by 2 or 3 Amino acid profiles in the two sides of cysteine in cyclic peptide, constitute link peptide
Amino acid can only be glycine or proline;
(3) epitope being made of containing one section 5-8 amino acid in cyclic peptide.
Preferably, one section of link peptide being connected in cyclic peptide with cysteine aminoterminal is made of glycine completely, with half Guang
Contain 1 to 2 proline in one section of connected link peptide of propylhomoserin c-terminus.
Specifically, when being used to screen the functional epitope (amino acid sequence that anti-human PD-1 75-82 amino acids are constituted
For QTDKLAAF) monoclonal antibody when, epitope peptide used in step 1 is cyclic annular and meets SEQ ID NO:13
Documented sequence;Cell strain used in step 2 is the cell strain in cell surface height expression people PD-1, it is preferred that this is thin
Born of the same parents' strain is the cell strain for the expression external source people's PD-1 gene being transformed using gene recombination technology, and under the cell strain native state
(i.e. before genetic modification) does not express PD-1, it is preferred that people PD-1 is that 10,000/cell arrives in the expression density of cell surface
500,000/cell.
A kind of antibody screened using the above method, combination people's PD-1 molecule 75-82 since N-terminal of energy specificity
Amino acids (amino acid sequence QTDKLAAF), complementary determining region CDR1, CDR2, CDR3 of the heavy chain of the antibody are respectively provided with
The amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, complementary determining region CDR1, CDR2 of light chain,
CDR3 is respectively provided with the amino acid sequence of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6.
Preferably, heavy chain variable region has the amino acid sequence of SEQ ID NO:7, and light chain variable region has SEQ ID
The amino acid sequence of NO:8.
Preferably, heavy chain is IgG4 hypotype, and the amino acid sequence with SEQ ID NO:9, light chain is with SEQ ID NO:
10 amino acid sequence.
Preferably, heavy chain is by the nucleotide sequence coded of SEQ ID NO:11, light chain by SEQ ID NO:12 nucleosides
Sequences code.
The antibody is by Chinese hamster ovary cell (Chinese hamster ovary celI) secreting, expressing.
Reverse transcriptase test (embodiment 6) and point mutation test (embodiment 7) show the antibody and Nivolumab and
Pembrolizumab has different combination epitopes, to cannot can also tie with the D85G point mutation PD-1 in conjunction with Pembrolizumab
It closes.
The antibody has IC50 value (embodiment 5) lower compared with Nivolumab and Pembrolizumab, can enhance people's T lymph
Cell can more effectively block the combination of PD-1 and PD-L1 to SEB stimulation responses ability (embodiment 8) under low dosage, and
Therapeutic effect (embodiment 9) is played to malignant tumour under lower dosage.
The antibody can be used to prepare treating malignant tumor drug and immune system disease individually or with other drugs, auxiliary material combination
Sick therapeutic agent.
Beneficial effects of the present invention include, can be by the function special to epitope using screening of phage antibody library method of the invention
The hit rate of energy property antibody is increased to 30% or more, greatly reduces the quantity and cost of clone identification.Anti- PD-1 Dan Ke of the invention
Grand antibody possesses epitope in conjunction with different people PD-1 from Nivolumab, Pembrolizumab, to cannot be with Pembrolizumab
In conjunction with point mutation PD-1 can also combine, and it is high with PD-1 affinity, have lower IC50 value, under low dosage more effectively
The combination of PD-1 and PD-L1 is blocked, and therapeutic effect played to malignant tumour under lower dosage, and low dosage antibody
There is positive effect to the stimulation of body, reduction drug cost and price using to reduction drug.
Detailed description of the invention
The special functional antibodies screening technique route map of Fig. 1 epitope
The Competitive assays experimental result picture that the anti-PD-1 monoclonal antibody 5L12 of the full source of people of Fig. 2 embodiment 5 combines PD-1/PD-L1
Other Competitive assays of anti-PD-1 antibody PD-1 monoclonal antibody 5L12 anti-to full source of people in conjunction with PD-1 of Fig. 3 embodiment 6
Experimental result picture
7 ELISA of Fig. 4 embodiment tests the binding ability of the PD-1 of the anti-PD-1 monoclonal antibody 5L12 of full source of people and D85G mutation
Experimental result picture
Survey of the anti-PD-1 monoclonal antibody 5L12 enhancing human T lymphocyte of the full source of people of Fig. 5 embodiment 8 to SEB stimulation responses ability
Try experimental result picture
Inhibiting tumor assay high dose group result figure of the anti-PD-1 monoclonal antibody 5L12 of the full source of people of Fig. 6 embodiment 9 in animal model
Inhibiting tumor assay low dose group result of the anti-PD-1 monoclonal antibody 5L12 of the full source of people of Fig. 7 embodiment 9 in animal model
Figure.
Specific embodiment
Embodiment 1, synthesis PD-1 epitope peptide screening phage displaying antibody library
(1) epitope peptide synthesis and magnetic bead are coupled
According to sequence chemical synthesis people's PD-1 ring-type epitope peptide (student on commission's work bioengineering (Shanghai) stock of SEQ ID NO:13
The synthesis of part Co., Ltd), which includes people PD-1 75-82 amino acids QTDKLAAF, and for the half of magnetic bead coupling
Each link peptide being made of 3 amino acid on cystine M and its both sides, 1475 Da of molecular weight.By synthetic epitope peptide with
10mg/mL is dissolved in PBS(phosphate buffer, pH7.2, sodium ascorbyl phosphate containing 20mM, 150mM sodium chloride) in it is spare;
By the derivative magnetic bead of 2mL amino, (Thermofisher Scientific company, article No. 21352, every mL magnetic bead weight are
2.5g contains about 12 μm of ol amino) it is cleaned with 2mL PBS, it cleans three times, magnetic separation magnetic bead;
By Sulfo-SMCC(Thermofisher Scientific company, article No. 22122) it is dissolved in the concentration of 4.8mg/mL
PBS takes 200 μ L to mix with above-mentioned magnetic bead, and 4 DEG C are reacted 2 hours;
Separation magnetic bead is simultaneously cleaned with PBS, magnetic bead is divided into two parts, portion is resuspended in PBST(of the 1mL containing 1%BSA containing 0.1%
The PBS of Tween 20) in, it is denoted as magnetic bead A;5 mL ring-type epitope peptides are added in another, and 4 DEG C are reacted 2 hours, and Beads enrichment is used
PBST cleaning, is resuspended in PBST of the 1mL containing 1%BSA, is denoted as magnetic bead B.
(2) phage displaying antibody library is screened
Each 20 mL of 50 healthy volunteer's blood is collected, is mixed, by the document " structure of natural humanized IgG Fab phage antibody library
Build and diversity analysis " (China Immunology Journal, 2010,26 (11): 1007-1010) method building phage display it is anti-
Body library.
The magnetic bead A and 1mL that step (1) is prepared with the PBST containing 1%BSA diluted phage displaying antibody library (5 ×
10^12 PFU) mixing, rotation mixing 1 hour at room temperature, magnetic force removes magnetic bead A, adds the magnetic bead prepared in step (1)
B, rotation mixing 1 hour, magnetic separation magnetic bead B, is cleaned magnetic bead B 3 times with PBST at room temperature, and 0.2 mol/L is added
Glycine-HCl (pH 2.2) solution mildly vibrates 20 min and the bacteriophage on magnetic bead B is washed lower collection, then uses 1mol/L
Tris-HCl(pH 9.1) it neutralizes, the phage-infect Escherichia coli (E. coli) of acquisition are expanded, secondary library is become,
It stores for future use.
Embodiment 2, PD-1 high express living cells postsearch screening functional antibodies
(1) cell strain in cell surface height expression PD-1 is constructed
(PDCD1 gene, containing N-terminal signal coding sequence, particular sequence is shown in NCBI to Cloning of full length PD-1 encoding gene
Reference Sequence:NM_005018.2), it is inserted into pcDNA3.1 expression vector, is expanded in Escherichia coli (E. coli)
293T cell (ATCC number CRL-3216) is transfected after increasing, overexpression cell line is screened, according to document " Flow cytometric
detection and quantitation of the epidermal growth factor receptor in
comparison to Scatchard analysis in human bladder carcinoma cell lines.
Cytometry. 1994 Sep 1;17 (1): 75-83 " and " Antibody- dependent cellular
cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin
Cancer Res. 2007 Mar 1;13 (5): the flow cytometry that 1552-61 " is recorded measures the PD-1 on each cell strain surface
Density is expressed, therefrom chooses the cell strain that the highest number of expression density is 2H-3, after measured the surface cell strain 2H-3 PD-1
Expressing density is averagely 12000/cell, and cell is used 293 SFM II serum free medium (Thermofisher
Scientific company, article No. 11686029) suspend culture, cell quantity is expanded to 5 × 10^6 or more.
(2) living cells screens anti-PD-1 antibody
The blank 293T cell that logarithmic phase is grown is resuspended in 1mL DMEM culture solution with 1 × 10^6 cell/mL density, is added
Enter embodiment 1(2) in screening obtain bacteriophage (being resuspended in after centrifugation in 1mL DMEM culture solution), after mixing 37 DEG C be incubated for 1
Hour, low-speed centrifugal removes cell, repeats the process 1 time, is screened with removing with the antibodies to "wrong" antigens of 293T cell combination, reduction
Background value;Then embodiment 2(1 is added in the supernatant of centrifugation) in 5 × 10^ of 2H-3 cell of high expression PD-1 for preparing
It 5, is incubated for 1 hour for 37 DEG C after mixing, low-speed centrifugal harvests cell, will with 1.5 times of 76 mM citric acid solutions (pH2.5) of volume
Bacteriophage is washed down from cell, is then neutralized with 0.5 times of volume Tris-HCl(pH7.4), will obtain phage-infect large intestine bar
Bacterium (E. coli) is expanded.
By embodiment 1(2) and embodiment 2(2) screening technique to previously obtained bacteriophage again successively carry out two-wheeled sieve
Choosing carries out monoclonal to the bacteriophage finally obtained and expands, and selects 60 clones using ELISA method and carries out bacteriophage pair
The identification of the compatibility and combination epitope of PD-1 is (with reference to " Journal of Immunology the 6th phase of volume 28 in June, 2012: 489-496 "
Phage-ELISA identification method), people's PD-1 extracellular fragment full-length proteins (20-170 amino acids) of recombinant expression are respectively adopted
96 orifice plates are coated with chemically synthesized people's PD-1 75-82 amino acids (sequence QTDKLAAF), and with chemically synthesized sequence
96 orifice plates are coated with as negative control for small peptides such as LDSPDR, LAPKAQ, RSQPGQ, then addition bacteriophage and HRP are marked anti-
Phage antibody is added the detection of HRP substrate chromogenic reaction and combines situation;Using flow cytometry identification bacteriophage to living cells
The compatibility of the surface 2H-3 PD-1;It obtains 22 ELISA and flow cytometry identification is positive in conjunction with PD-1 and combines PD-
The clone of 1 defined epitope (75-82 amino acids QTDKLAAF), positive rate is up to 36.67%.
Embodiment 3, the complete anti-PD-1 monoclonal antibody expression system of source of people of building
(1) identification of heavy chain and light chain variable region
From 22 bacteriophage positive colonies that embodiment 2 finally obtains, picks out 5 and identify that compatibility is higher through ELISA
Clone is sequenced, and the clone that preferably out 1 number is 5L12 is further developed.Sequencing result shows the heavy chain of 5L12
Variable region has the amino acid sequence of SEQ ID NO:7, and light chain variable region has the amino acid sequence of SEQ ID NO:8, into
One step antibody sequence analysis shows, complementary determining region CDR1, CDR2, CDR3 of heavy chain are respectively provided with SEQ ID NO:1, SEQ ID
The amino acid sequence of NO:2, SEQ ID NO:3, complementary determining region CDR1, CDR2, CDR3 of light chain are respectively provided with SEQ ID
The amino acid sequence of NO:4, SEQ ID NO:5, SEQ ID NO:6.
(2) building and transfection of expression vector
Using the light and weight chain variable region gene sequence of 5L12 as template, the heavy chain gene of human antibody is synthesized by over-lap PCR
(IgG4 type), light chain gene, wherein the coded sequence of heavy chain is the nucleotide sequence of SEQ ID NO:11,5 ' end signal of heavy chain
The coded sequence of peptide is the nucleotide sequence of SEQ ID NO:14, and the coded sequence of light chain is the nucleotide of SEQ ID NO:12
Sequence.The coded sequence of heavy chain, light chain is inserted into pcDNA3.1 (+) carrier (Invitrogen company), constructs the anti-PD- of full source of people
The expression vector pcDNA3.1-anti-PD-1 of 1 monoclonal antibody, is carried out with Lipofectamine2000Reagent kit
It transfects CHO-K1 cell (ATCC number CRL-9618), with G418 and Zeocin screening positive clone, then takes in cell culture
Clear liquid screens overexpression cell line with ELISA method, and transfection, the specific experiment process screened are according to patent CN201010125241
The embodiment of (Authorization Notice No. CN102167742B) carries out.
(3) a small amount of expression and purifications
The overexpression cell line that screening is obtained is expanded with Chinese hamster ovary celI serum free medium to be cultivated, with Protein A affinity column
(GE Products) isolate and purify human antibody 5L12, and the antibody of purifying is dialysed with PBS, finally with ultraviolet suction
Receive standard measure.
The determination of the anti-PD-1 monoclonal antibody 5L12 affinity of embodiment 4, full source of people
The anti-PD-1 monoclonal antibody 5L12 of full source of people prepared using Surface Plasmon Resonance (SPR) measurement embodiment 3 is to people
The affinity of PD-1.Using BIACORE3000 system, with purified 5L12 antibody coupling sensing chip, according to the behaviour of system
It explains book to be operated, detecting the PD-1 extracellular fragment full-length proteins that 5L12 and Chinese hamster ovary celI recombinantly express respectively, (NCBI refers to sequence
Arrange NM_005018.2 20-170 amino acids) and chemically synthesized PD-1 75-82 amino acids (sequence QTDKLAAF) with
And sequence is the affinity of the small peptide of LDSPDR, LAPKAQ, RSQPGQ, testing result is shown in Table 1,5L12 to PD-1 extracellular fragment overall length
And the affinity of epitope peptide QTDKLAAF is up to 10-11M grades.
1 SPR method of table measures the result of full source of people anti-PD-1 monoclonal antibody 5L12 and different peptide fragment compatibilities
The anti-PD-1 monoclonal antibody 5L12 of embodiment 5, full source of people tests the Competitive assays that PD-1/PD-L1 is combined
The human PD-L 1 born of the same parents for being recombinantly expressed albumen PD-L1(CHO cell to be marked with the carbonate buffer solution of 0.025M pH9.5
Outer segment) it is diluted to 1%(mass volume ratio) concentration, it is fitted into bag filter.FITC is made into the molten of 0.1mg/ml with same buffer
Liquid is contained in small beaker, is immersed in bag filter in FITC solution, and stirring is protected from light at 4 DEG C for 24 hours.Marking fluid in bag filter is taken out,
Column is crossed with Sephadex G-50, free fluorescein is removed, it is spare to collect fluorescence antibody FITC-PD-L1.
By the genetic recombination 293T cell of surface expression people PD-1 with 1 × 106Cell/ml density is resuspended in pH7.2's
In PBS solution;By the fluorescent marker protein FITC-PD-L1 of fixed sub-saturated concentration respectively and with 4 × not marking of being serially diluted
Remember antibody purification 5L12, Nivolumab(Opdivo), Pembrolizumab(Keytruda), human IgG (control) mixing, addition
Into cell suspension, in 4 DEG C of 60 min of incubation, cell is harvested by centrifugation, washes 2 times with 1% FCS-PBS buffer, flow cytometer
It detects cell fluorescence intensity and is analyzed with Cellquest software.Each concentration of competition antibody sets 3 multiple pipes, calculates half suppression
Concentration IC50 value processed, maximum fluorescence intensity indicate the average fluorescent strength obtained in no competition antibody.
Experimental result is shown in Fig. 2, show that antibody 5L12 can block fluorescent labeled antibody FITC-PD-L1 and surface expression completely
The combination of the 293T cell of PD-1, IC50 value are about 30 ng/mL, are the 1/ of Nivolumab, Pembrolizumab respectively
20,1/2, show that 5L12 can more effectively block PD-1 and the combination of its ligand, the minimum dose that can play effect is lower.
The competition suppression of embodiment 6, other anti-PD-1 antibody PD-1 monoclonal antibody 5L12s anti-to full source of people in conjunction with PD-1
System experiment
FITC label is carried out to 5L12 with the method for embodiment 5, preparation FITC-5L12 fluorescence antibody is spare.
By the genetic recombination 293T cell of surface expression people PD-1 with 1 × 106Cell/ml density is resuspended in pH7.2's
In PBS solution;By the fluorescent marker protein FITC-5L12 of fixed sub-saturated concentration respectively and with 10 × not marking of being serially diluted
Remember antibody Nivolumab(Opdivo), Pembrolizumab(Keytruda), human IgG (control) mixing, be added to cell hang
In liquid, in 4 DEG C of 60 min of incubation, cell is harvested by centrifugation, is washed 2 times with 1% FCS-PBS buffer, flow cytomery cell
Fluorescence intensity is simultaneously analyzed with Cellquest software.Each concentration of competition antibody sets 3 multiple pipes, and maximum fluorescence intensity indicates
The average fluorescent strength obtained when not competing antibody.
Experimental result is shown in Fig. 3, the results showed that Pembrolizumab makees the Competitive assays that are combined with of 5L12 and people PD-1
With, and Nivolumab does not have apparent competitive inhibitory effect to 5L12, this illustrate combination epitope of the 5L12 on people PD-1 with
Nivolumab(is 25LDSPDR30, bibliography: An unexpected N-terminal loop in mainly in combination with epitope
PD-1 dominates binding by nivolumab. Nature Communications, 2017,8:14369) no
Together, but and Pembrolizumab(mainly in combination with epitope be Pro83~Gly90, bibliography: High-resolution
crystal structure of the therapeutic antibody pembrolizumab bound to the
2016,6, Article number:35297 of human PD-1. Scientific Reports.) it is close, or
The combination of Pembrolizumab and PD-1 spatially hinders the combination of 5L12 and PD-1.
Ability of the anti-PD-1 monoclonal antibody 5L12 of embodiment 7, full source of people in conjunction with the PD-1 that D85G is mutated
It by the 85th Aspartic acid mutations of people PD-1 is glycine (D85G mutation) by the method for genetic recombination, by people PD-1 born of the same parents
Outer segment and people PD-1 extracellular fragment (D85G) encoding gene are inserted into pcDNA3.1 carrier and transfection CHO cell respectively, carry out instantaneous table
It reaches, purify.
By the concentration of purifying be 1 mg/mL people PD-1 extracellular fragment and people PD-1 extracellular fragment (D85G) albumen with 100 μ L/
Hole is coated with 96 orifice plates respectively, and 96 orifice plates are added with 100 holes μ L/, so in the carry out 10 × be serially diluted since 1 mg/mL by 5L12
The rabbit anti-human igg of HRP label is added afterwards, carries out chromogenic reaction, reads data with microplate reader.ELISA result is shown in Fig. 4, as a result table
Bright 5L12 can be combined with people PD-1 extracellular fragment and people PD-1 extracellular fragment (D85G), and Pembrolizumab report cannot be with
The PD-1 of D85G mutation combines (bibliography: Structural basis for blocking PD-1-mediated
immune suppression by therapeutic antibody pembrolizumab. Cell Research 2017.
27:147-150.), illustrate that 5L12 there are different binding sites from Pembrolizumab.
The anti-PD-1 monoclonal antibody 5L12 enhancing human T lymphocyte of embodiment 8, full source of people is to SEB stimulation responses ability
Test
Peripheral blood from healthy volunteer is diluted in cell culture medium with 1: 10, whole blood bed board (every 150 μ L of hole) arrives
In 96- orifice plate, with 10 × be serially diluted full source of people anti-PD-1 monoclonal antibody 5L12 preincubate 30-60 minutes, then it is added 1
The staphylococcal enterotoxin B (SEB) of μ g/mL is cultivated 2-4 days, and supernatant is collected, and measures wherein IL-2 content with ELISA, as a result
See Fig. 5, shows that 5L12 can improve IL-2 of the whole blood cells under SEB stimulation and generate, and the additive of IL-2 level and 5L12
Measurer has correlation.
Inhibiting tumor assay of the anti-PD-1 monoclonal antibody 5L12 of embodiment 9, full source of people in animal model
1, the building of human PBMC's immunologic reconstitution mouse
User's lymphocyte separation medium, separation comes from health donors human PBMC (peripheral blood mononuclear cells), with 8 × 107/mL
It is resuspended in spare in RPMI-1640 culture medium;Select the NOD/SCID adult mice of the μ of mouse IgG < 5 g/mL in serum, tail vein note
Penetrate 2 × 107PBMC cell, took 250 μ L of peripheral blood from mouse orbit rear vein beard at the 0th, 14,28,42,56 day respectively, make
Mouse anti human CD 19 monoclonal antibody combination flow cytomery CD3+T with the mouse antibody human CD3 monoclonal antibody of PE label, FITC label is thin
Born of the same parents, CD19+B cell content, using human IgG content in ELISA method measurement mice serum, to determine immunologic reconstitution effect.
2, it constructs mouse tumor model and is treated using anti-human PD-1 antibody 5L12
Non-small cell lung carcinoma cell strain HCC827(high expresses PD-L1) with 1 × 106Cell/only dose subcutaneous be implanted to people
PBMC immunologic reconstitution mouse, to tumour growth to 250mm after implantation2After start to give anti-PD-1 treatment.Mouse is divided into high agent
Amount group and low dose group, high dose group are given the 5L12(of 3 mg/kg respectively and are dissolved in PBS with the concentration of 1 mg/mL),
Nivolumab, Pembrolizumab are administered once for every 10 days, are administered 4 times, measure tumor size with caliper every 1 week;It is low
The dosage of dosage group is adjusted to 0.5 mg/kg, other test methods are constant;And use PBS as control.
Experimental result is shown in Fig. 6 and Fig. 7, show that 5L12 can play apparent inhibition to tumour growth under low dosage and make
With effective dose is significantly lower than Nivolumab, Pembrolizumab.
Sequence table
<110>Taizhou Mai Botaike pharmaceutcal corporation, Ltd
<120>a kind of antibody screening method that epitope is special and the antibody screened
<130> 2017
<160> 14
<170> SIPOSequenceListing 1.0
<210> 1
<211> 7
<212> PRT
<213>artificial sequence ()
<400> 1
Gly Tyr Thr Phe Thr Ser Tyr
1 5
<210> 2
<211> 6
<212> PRT
<213>artificial sequence ()
<400> 2
Tyr Pro Ser Thr Gly Tyr
1 5
<210> 3
<211> 8
<212> PRT
<213>artificial sequence ()
<400> 3
Gly Val Arg Tyr Tyr Phe Asp Tyr
1 5
<210> 4
<211> 17
<212> PRT
<213>artificial sequence ()
<400> 4
Lys Ser Ser Gln Ser Leu Leu Asp Ser Ser Thr Arg Lys Asn Tyr Leu
1 5 10 15
Ala
<210> 5
<211> 7
<212> PRT
<213>artificial sequence ()
<400> 5
Trp Ala Ser Thr Arg Glu Ser
1 5
<210> 6
<211> 7
<212> PRT
<213>artificial sequence ()
<400> 6
Lys Gln Ser Tyr Asn Leu Trp
1 5
<210> 7
<211> 117
<212> PRT
<213>artificial sequence ()
<400> 7
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Trp Met Leu Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Tyr Ile Tyr Pro Ser Thr Gly Tyr Thr Glu Tyr Ser Glu Asn Phe
50 55 60
Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Val Arg Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu
100 105 110
Val Thr Val Ser Ser
115
<210> 8
<211> 113
<212> PRT
<213>artificial sequence ()
<400> 8
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser
20 25 30
Ser Thr Arg Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys
35 40 45
Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Lys Gln
85 90 95
Ser Tyr Asn Leu Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105 110
Arg
<210> 9
<211> 444
<212> PRT
<213>artificial sequence ()
<400> 9
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Trp Met Leu Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Tyr Ile Tyr Pro Ser Thr Gly Tyr Thr Glu Tyr Ser Glu Asn Phe
50 55 60
Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Val Arg Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu
100 105 110
Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
115 120 125
Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys
130 135 140
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
145 150 155 160
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
165 170 175
Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
180 185 190
Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn
195 200 205
Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro
210 215 220
Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe
225 230 235 240
Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
245 250 255
Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe
260 265 270
Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
275 280 285
Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
290 295 300
Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
305 310 315 320
Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala
325 330 335
Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln
340 345 350
Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
355 360 365
Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
370 375 380
Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
385 390 395 400
Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu
405 410 415
Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
420 425 430
Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys
435 440
<210> 10
<211> 219
<212> PRT
<213>artificial sequence ()
<400> 10
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser
20 25 30
Ser Thr Arg Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys
35 40 45
Ala Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Lys Gln
85 90 95
Ser Tyr Asn Leu Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105 110
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
115 120 125
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
130 135 140
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
145 150 155 160
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
165 170 175
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
180 185 190
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
195 200 205
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
210 215
<210> 11
<211> 1332
<212> DNA
<213>artificial sequence ()
<400> 11
gaggtgcagc tggtggagtc cggcggcggc ctggtgcagc ccggcggctc cctgcggctg 60
tcctgcgccg cctccggcta caccttcacc tcctactgga tgctgtgggt gcggcaggcc 120
cccggcaagg gcctggagtg ggtgtcctac atctacccct ccaccggcta caccgagtac 180
tccgagaact tcaaggaccg gttcaccatc tcccgggaca actccaagaa caccctgtac 240
ctgcagatga actccctgcg ggccgaggac accgccgtgt actactgcgc ccggggcgtg 300
cggtactact tcgactactg gggccagggc accctggtga ccgtgtcctc cgcctccacc 360
aagggcccct ccgtgttccc cctggccccc tgctcccggt ccacctccga gtccaccgcc 420
gccctgggct gcctggtgaa ggactacttc cccgagcccg tgaccgtgtc ctggaactcc 480
ggcgccctga cctccggcgt gcacaccttc cccgccgtgc tgcagtcctc cggcctgtac 540
tccctgtcct ccgtggtgac cgtgccctcc tcctccctgg gcaccaagac ctacacctgc 600
aacgtggacc acaagccctc caacaccaag gtggacaagc gggtggagtc caagtacggc 660
cccccctgcc ccccctgccc cgcccccgag ttcctgggcg gcccctccgt gttcctgttc 720
ccccccaagc ccaaggacac cctgatgatc tcccggaccc ccgaggtgac ctgcgtggtg 780
gtggacgtgt cccaggagga ccccgaggtg cagttcaact ggtacgtgga cggcgtggag 840
gtgcacaacg ccaagaccaa gccccgggag gagcagttca actccaccta ccgggtggtg 900
tccgtgctga ccgtgctgca ccaggactgg ctgaacggca aggagtacaa gtgcaaggtg 960
tccaacaagg gcctgccctc ctccatcgag aagaccatct ccaaggccaa gggccagccc 1020
cgggagcccc aggtgtacac cctgcccccc tcccaggagg agatgaccaa gaaccaggtg 1080
tccctgacct gcctggtgaa gggcttctac ccctccgaca tcgccgtgga gtgggagtcc 1140
aacggccagc ccgagaacaa ctacaagacc accccccccg tgctggactc cgacggctcc 1200
ttcttcctgt actcccggct gaccgtggac aagtcccggt ggcaggaggg caacgtgttc 1260
tcctgctccg tgatgcacga ggccctgcac aaccactaca cccagaagtc cctgtccctg 1320
tccctgggca ag 1332
<210> 12
<211> 657
<212> DNA
<213>artificial sequence ()
<400> 12
gacatccaga tgacccagtc cccctcctcc ctgtccgcct ccgtgggcga ccgggtgacc 60
atcacctgca agtcctccca gtccctgctg gactcctcca cccggaagaa ctacctggcc 120
tggtaccagc agaagcccgg caaggccccc aagctgctga tctactgggc ctccacccgg 180
gagtccggcg tgccctcccg gttctccggc tccggctccg gcaccgactt caccctgacc 240
atctcctccc tgcagcccga ggacttcgcc acctactact gcaagcagtc ctacaacctg 300
tggaccttcg gccagggcac caaggtggag atcaagcgga ccgtggccgc cccctccgtg 360
ttcatcttcc ccccctccga cgagcagctg aagtccggca ccgcctccgt ggtgtgcctg 420
ctgaacaact tctacccccg ggaggccaag gtgcagtgga aggtggacaa cgccctgcag 480
tccggcaact cccaggagtc cgtgaccgag caggactcca aggactccac ctactccctg 540
tcctccaccc tgaccctgtc caaggccgac tacgagaagc acaaggtgta cgcctgcgag 600
gtgacccacc agggcctgtc ctcccccgtg accaagtcct tcaaccgggg cgagtgc 657
<210> 13
<211> 15
<212> PRT
<213>artificial sequence ()
<400> 13
Cys Pro Pro Ala Gln Thr Asp Lys Leu Ala Ala Phe Ala Ala Ala
1 5 10 15
<210> 14
<211> 66
<212> DNA
<213>artificial sequence ()
<400> 14
atggattttc aggtgcagat tttcagcttc ctgctaatca gtgcctcagt cataatatcc 60
agagga 66
Claims (10)
1. a kind of screening technique for the functional antibodies that epitope is special, characterized in that including following two screening step:
Step 1: synthetic antigen epitope peptide is simultaneously coupled on solid-phase media, and first run screening is carried out from phage displaying antibody library,
It obtains and the bacteriophage of epitope peptide specific binding and amplification;
Step 2: obtaining or building is in the cell strain of cell surface height expression purpose antigen, is obtained with living cells from first run screening
Bacteriophage in further bacteriophage of the screening in conjunction with cell surface antigen.
2. according to the method described in claim 1, it is characterized in that, epitope peptide described in step 1 is by 10 to 15 amino
The cyclic peptide of acid composition, the Amino acid profile of cyclic peptide meet the following conditions:
Have in cyclic peptide and only 1 cysteine, cyclic peptide pass through on the sulfydryl covalent coupling to solid-phase media of the cysteine;
Respectively there are one section of link peptide by 2 or 3 Amino acid profiles in the two sides of cysteine in cyclic peptide, constitute the amino of link peptide
Acid can only be glycine or proline;
The epitope being made of containing one section 5-8 amino acid in cyclic peptide.
3. according to the method described in claim 2, it is characterized in that, one section of link peptide being connected in cyclic peptide with cysteine aminoterminal
It is made of completely glycine, 1 to 2 proline is contained in one section of link peptide being connected with cysteine c-terminus.
4. a kind of screening technique of the special anti-human PD-1 functional antibodies of epitope, characterized in that using described in claim 1
Method, and epitope peptide used in step 1 is the cyclic peptide with amino acid sequence documented by SEQ ID NO:13,
Cell strain used in step 2 is the cell strain of cell surface height expression PD-1, and PD-1 is in the expression quantity of cell surface
10,000/cell is to 500,000/cell.
5. a kind of antibody screened using method described in claim 1, can specificity combination people's PD-1 molecule it is extracellular
Section, characterized in that complementary determining region CDR1, CDR2, CDR3 of heavy chain be respectively provided with SEQ ID NO:1, SEQ ID NO:2,
The amino acid sequence of SEQ ID NO:3, complementary determining region CDR1, CDR2, CDR3 of light chain be respectively provided with SEQ ID NO:4,
The amino acid sequence of SEQ ID NO:5, SEQ ID NO:6.
6. antibody according to claim 5, characterized in that heavy chain variable region has the amino acid sequence of SEQ ID NO:7
Column, light chain variable region have the amino acid sequence of SEQ ID NO:8.
7. antibody according to claim 5, characterized in that heavy chain has the amino acid sequence of SEQ ID NO:9, light chain
Amino acid sequence with SEQ ID NO:10.
8. antibody according to claim 5, characterized in that heavy chain is nucleotide sequence coded by SEQ ID NO:11's, gently
Chain is nucleotide sequence coded by SEQ ID NO:12's.
9. a kind of composition contains monoclonal antibody as claimed in claim 6 and pharmaceutically acceptable carrier.
10. antibody described in claim 6-9 is in preparing treating malignant tumor drug and disease of immune system therapeutic agent
Purposes.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711375292.7A CN109929036A (en) | 2017-12-19 | 2017-12-19 | A kind of antibody screening method that epitope is special and the antibody screened |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711375292.7A CN109929036A (en) | 2017-12-19 | 2017-12-19 | A kind of antibody screening method that epitope is special and the antibody screened |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109929036A true CN109929036A (en) | 2019-06-25 |
Family
ID=66983728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711375292.7A Pending CN109929036A (en) | 2017-12-19 | 2017-12-19 | A kind of antibody screening method that epitope is special and the antibody screened |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109929036A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110656092A (en) * | 2019-11-06 | 2020-01-07 | 新乡学院 | Cell model for displaying PD-1 protein containing double signal peptides on cell membrane surface and application thereof |
WO2021043337A1 (en) * | 2019-09-06 | 2021-03-11 | 中国药科大学 | Polypeptide and application thereof |
WO2021197212A1 (en) * | 2020-03-30 | 2021-10-07 | 华东理工大学 | Phage drug-protein display system and use thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060275288A1 (en) * | 2005-01-20 | 2006-12-07 | Grihalde Nelson D | GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof |
CN104292308A (en) * | 2014-08-22 | 2015-01-21 | 广州安辰医药科技有限公司 | Novel tumor antigen cyclopeptide |
CN104447993A (en) * | 2013-09-13 | 2015-03-25 | 上海海思太科药业有限公司 | Human anti-HER2 monoclonal antibody with high activity, and preparation method and application thereof |
US20190231872A1 (en) * | 2016-08-17 | 2019-08-01 | Industry Academic Cooperation Foundation, Hallym University | A vaccine composition comprising cyclic peptides, antibodies to the cyclic peptides or an anticancer composition comprising the same |
-
2017
- 2017-12-19 CN CN201711375292.7A patent/CN109929036A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060275288A1 (en) * | 2005-01-20 | 2006-12-07 | Grihalde Nelson D | GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof |
CN104447993A (en) * | 2013-09-13 | 2015-03-25 | 上海海思太科药业有限公司 | Human anti-HER2 monoclonal antibody with high activity, and preparation method and application thereof |
CN104292308A (en) * | 2014-08-22 | 2015-01-21 | 广州安辰医药科技有限公司 | Novel tumor antigen cyclopeptide |
US20190231872A1 (en) * | 2016-08-17 | 2019-08-01 | Industry Academic Cooperation Foundation, Hallym University | A vaccine composition comprising cyclic peptides, antibodies to the cyclic peptides or an anticancer composition comprising the same |
Non-Patent Citations (3)
Title |
---|
SANG JICK KIM等: "Selection of an affinity-matured antibody against a defined epitope by phage display of an immune antibody library", 《JOURNAL OF IMMUNOLOGICAL METHODS》, vol. 329, no. 1, 9 November 2007 (2007-11-09) * |
宋宏彬等: "人源抗HIV-1 V3环噬菌体抗体筛选与鉴定", 《中国公共卫生》, vol. 24, no. 7, 1 September 2008 (2008-09-01) * |
罗龙龙: "基于表位定向哺乳动物细胞抗体库筛选新型抗PD-1抗体", 《中国知网》, 31 December 2016 (2016-12-31) * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021043337A1 (en) * | 2019-09-06 | 2021-03-11 | 中国药科大学 | Polypeptide and application thereof |
CN110656092A (en) * | 2019-11-06 | 2020-01-07 | 新乡学院 | Cell model for displaying PD-1 protein containing double signal peptides on cell membrane surface and application thereof |
WO2021197212A1 (en) * | 2020-03-30 | 2021-10-07 | 华东理工大学 | Phage drug-protein display system and use thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11897967B2 (en) | Humanized anti-MUC1* antibodies | |
CN108864290B (en) | Bispecific recombinant protein and application thereof | |
US20220315658A1 (en) | Anti-pd-l1 single-domain antibody and derivatives and use thereof | |
CN103619882B (en) | The φt cell receptor sample antibody that the WT1 peptide of presenting HLA-A2 is special | |
CN105473615B (en) | Anti-cd 38 antibodies and with cause weak jamming element α -2B fusion | |
AU2018392741B2 (en) | Antibodies to tumour antigens | |
CN110462038A (en) | Anti- GPRC5D antibody and the molecule comprising the antibody | |
CN104936980B (en) | For treating and preventing the recombinant human antibody of the relevant disease of polyomavirus | |
CN110392697A (en) | There is the antibody and application thereof of specificity to NECTIN-4 | |
US20210261667A1 (en) | Blocking type pd-l1 single-domain camel antibody and application thereof | |
CN110139873A (en) | HPV specific binding molecules | |
UA126802C2 (en) | Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof | |
CN110392696A (en) | Anti-Human 4-1BB antibody and its application | |
CN110088133A (en) | Anti-idiotype and correlation technique | |
KR102332847B1 (en) | Antibodies Against T cell Immunoreceptor with Ig and Tyrosine-Based Inhibitory Motif Domains and Uses Thereof | |
CN110177808A (en) | For the Chimeric antigen receptor and its application method of AXL or ROR2 | |
CN109069573A (en) | In conjunction with the single domain antibody of CD20 | |
EP3766901A1 (en) | Antibody targeting ctla-4 , preparation method therefor and use thereof | |
UA118950C2 (en) | Prostate-specific membrane antigen binding proteins and related compositions and methods | |
JP2021512635A (en) | Chimeric antigen receptor targeting the tumor microenvironment | |
AU2018256392B2 (en) | Anti-PD-L1 antibody and use thereof | |
CN102164962A (en) | Anti-GD2 antibodies and methods and uses related thereto | |
CN110291108A (en) | Novel TNFR agonist and application thereof | |
CN109069627A (en) | To the T cell receptor sample antibody of the derivative peptide specific of FOXP3 | |
CN109929036A (en) | A kind of antibody screening method that epitope is special and the antibody screened |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |